# Defective interferon-gamma production in patients with hairy cell leukaemia

M.G. Netea<sup>1,3\*</sup>, O. Hoitink<sup>1</sup>, B.J. Kullberg<sup>1,3</sup>, J.W.M. van der Meer<sup>1,3</sup>, R. Raymakers<sup>2</sup>

Divisions of 'General Internal Medicine and <sup>2</sup>Haematology, Radboud University Nijmegen Medical Center, <sup>3</sup>Nijmegen University Center for Infectious Diseases, Nijmegen, the Netherlands, \*corresponding author: tel.: +31 (0)24-361 88 19, e-mail: m.netea@aig.umcn.nl

#### ABSTRACT

Background: Patients with hairy cell leukaemia (HCL) have an increased susceptibility to intracellular pathogens, such as mycobacteria and *Listeria*. Although several abnormalities of T-cell populations have been described in HCL, the effector mechanism responsible for the increased susceptibility to infections is not known.

Methods: Blood was collected from 11 patients with HCL and 22 age- and gender-matched volunteers. Proinflammatory cytokine production by freshly isolated mononuclear cells was stimulated with either lipopoly-saccharide or various heat-killed microorganisms. Cytokine concentrations were assessed by specific ELISAs.

Results: We demonstrate that mononuclear cells harvested from HCL patients have a specific defect of IFN $\gamma$  production when stimulated with a broad panel of bacterial stimuli. In contrast, the production of other proinflammatory cytokines, such as TNF, IL-1 $\beta$  and IL-6, did not differ between HCL patients and controls.

Conclusion: The specific defect in IFN $\gamma$  production may play a role in the susceptibility of patients with hairy cell leukaemia towards intracellular pathogens.

## KEYWORDS

Cytokines, hairy cell leukaemia, interferon-gamma, mycobacteria

# INTRODUCTION

Hairy cell leukaemia (HCL) is a chronic B-lymphocyte malignancy, in which mature neoplastic B lymphocytes show hair-like protrusions. A major characteristic of HCL is splenomegaly, due to accumulation of malignant cells. In HCL, opportunistic infections, especially with facultative

intracellular pathogens such as mycobacteria or *Listeria*, are prominent.<sup>2</sup> The occurrence of these infections suggests a serious defect in the cellular immune defence provided by T lymphocytes and macrophages.<sup>3</sup>

Although HCL is a B-cell malignancy, a series of abnormalities in the function of T cells have been also reported. There is abnormal T-cell activation, proliferation, clonal expansion and distribution; there is a decrease in memory T helper cells, an increase in splenic CD<sub>3</sub>-positive T cells positive for gamma delta T-cell receptors, and a restricted and skewed repertoire of the T-cell receptor family.<sup>4-7</sup> Although these abnormalities all point to T-lymphocyte dysfunction, the exact mechanism behind the increased susceptibility to facultative intracellular infection is not clear.

In recent years, an increased susceptibility to mycobacteria and Salmonella species has been described in patients with genetic defects in the interleukin-12/interferon-gamma (IL-12, IFN $\gamma$ ) macrophage activation route. § In these patients, the defects result in impaired IFN $\gamma$  signalling, required to activate the microbicidal capacity of macrophages.

In the present study we have assessed the production of IFN $\gamma$  by peripheral blood cells of patients with HCL, to obtain a better insight into the effector arm of cellular immunity in this disease. Since cytokines other than IFN $\gamma$  are also relevant for host defence against infection, and cytokine production is regulated within what is known as the cytokine network, we measured a series of other relevant proinflammatory cytokines.

## PATIENTS AND METHODS

# **Patients**

Eleven patients diagnosed with HCL were included in the study (see *table 1* for clinical characteristics). Two of these patients had a mycobacterial infection at clinical

Patient	Gender	Year of diagnosis	HCL therapy	Mycobacterial infections	Monocytes (x 10³/ml)
I	M	1987	IFN $\alpha$	No	70
2	M	1983	IFNα 2-CDA	No	56
3	M	1994	2-CDA	No	232
4	M	1992	IFNα	No	106
5	M	1984	Splenectomy		
			IFN $\alpha$	No	803
6	M	1995	2-CDA	Mycobacterial lymphadenitis	324
7	M	1996	IFN $\alpha$	No	128
8	F	2000	IFNα G-CSF	Disseminated M. kansasii	117
9	M	1986	IFN $\alpha$	No	264
10	M	2000	2-CDA	No	406
II	M	1983	Splenectomy IFNα	No	690

presentation. These patients had completely recovered from this infectious episode at the time of the present study. Patients had been treated previously with either cladribine (2-CDA), IFN $\alpha$  or a combination of both. Medication was stopped at least two weeks prior to the assessment of cytokine production. All samples were obtained between 9 am and 11 am, and for each patient, two gender-matched volunteers were concomitantly tested (n=22, 20 men and 2 women, age 26  $\pm$  7 years).

# Ex-vivo stimulation of cytokine production

After obtaining informed consent, venous blood was drawn from the cubital vein of patients and healthy volunteers into three 10 ml EDTA tubes (Monoject). Isolation of mononuclear cells (MNC) was performed as described, with minor modifications. The MNC fraction was obtained by density centrifugation of blood diluted 1:1 in pyrogen-free saline over Ficoll-Paque (Pharmacia Biotech). Cells were washed twice in saline and suspended in culture medium (RPMI 1640 DM) supplemented with gentamicin 10  $\mu$ g/ml, L-glutamine 10 mM and pyruvate 10 mM. The cells were counted in a Coulter counter (Coulter Electronics) and the number was adjusted to 5 x 106 cells/ml. The MNC population consisted of approximately 80% lymphocytes and 20% monocytes, and no differences between patients and controls were apparent.

5 x 10<sup>5</sup> MNC in a 100 μl volume were added to round-bottom 96-well plates (Greiner) and incubated with either 100 μl of culture medium (negative control), or one of the various stimuli: 10 ng/ml LPS (S. typhimurium; Sigma Chemical), or 1 x 10<sup>6</sup> microorganisms/ml heat-killed (30 min, 100°C) S. typhimurium, Staphylococcus aureus, Mycobacterium tuberculosis or Candida albicans. After 24 hours (TNF, IL-1β and IL-6) or 48 hours (IFNγ) incubation at 37°C, supernatants were collected and cytokine concentrations

were measured using specific ELISA kits (Pelikine, Sanquin, Amsterdam).


#### Statistical analysis

The experiments were performed in duplicate with blood obtained from patients and volunteers, and the data are presented as cumulative results of all experiments performed. The differences between groups were analysed by the Mann-Whitney U test. The level of significance between groups was set at p<0.05. The data are given as means ± SD.

# RESULTS AND DISCUSSION

When MNC of HCL patients were stimulated with LPS or a panel of microorganisms, the IFN $\gamma$  production after 48 hours of stimulation was significantly lower compared with healthy volunteers (*figure 1A*). In contrast, the production of the proinflammatory cytokines TNF $\alpha$ , IL-1 $\beta$  and IL-6 did not differ between HCL patients and controls (*figure* 1B-D). The specific defect in IFN $\gamma$  production, in contrast to the normal synthesis of monocyte products such as TNF $\alpha$ , IL-1 $\beta$  and IL-6, suggests a selective T/NK-cell defect in HCL patients, and is not part of a more general defect in cytokine production. It is tempting to assume that such defective production also occurs *in vivo* and underlies the remarkable susceptibility of HCL patients to facultative intracellular pathogens.

Our finding that TNF $\alpha$  production is normal is remarkable, since elevated serum concentrations of TNF $\alpha$  have been reported in patients with HCL. <sup>10,11</sup> As far as we know, defective IFN $\gamma$  production has not been reported previously, despite the fact that there is extensive literature on T-lymphocyte abnormalities in this disorder. <sup>47</sup> Cytokine gene expression in patients with HCL has been reported



PBMC from healthy volunteers (n=22, open bars) and HCL patients (n=11, closed bars) were stimulated with LPS (10 ng/ml), or heat-killed S. typhimurium, S. aureus, M. tuberculosis, or C. albicans. The cytokine concentrations were measured in the supernatant after 48 hours (IFN $\gamma$ ) or 24 hours (TNF, IL-1 $\beta$ , and IL-6). The data are expressed as means  $\pm$  SD, \*p<0.05.

by Kluin-Nelemans *et al.*<sup>4</sup> These authors investigated cytokine mRNA in T-cell fractions from spleens of HCL patients, and found spontaneous gene expression for IFN $\gamma$  IL-2, IL-4 and granulocyte-macrophage colony stimulating factor (GM-CSF). Their finding of increased IFN $\gamma$  mRNA in spleen and our report of strongly decreased IFN $\gamma$  production may suggest that there is either a translational defect in these T cells, or a compartimentalised IFN $\gamma$  production. Further studies are needed to elucidate this issue.

Decreased IFNγ production as a likely explanation for infections caused by facultative intracellular microorganisms, such as mycobacteria, has been reported for a number of conditions. First of all, there are hereditary disorders of the IL-12/IFNγ axis.<sup>12,13</sup> In CD4 lymphopenia, either as a consequence of HIV infection or idiopathic, IFNγ production is low due to the loss of CD4 cells.<sup>14,15</sup> In addition, in hyperIgE syndrome (HIES/Job's syndrome), deficient IFNγ production has been found when blood cells were stimulated with relevant microbial stimuli (*Staphylococcus* and *Candida* spp.).<sup>16,17</sup> It should be noted that in these patients, the susceptibility to infection pertains to the pathogens mentioned, rather than to facultative intracellular pathogens.<sup>18</sup> A similar finding has been described in chronic

mucocutaneous candidiasis. <sup>19</sup> Finally, anti-TNF $\alpha$  treatment in patients with rheumatoid arthritis may lead to deficient IFN $\gamma$  production and infections by both facultative intracellular pathogens and pyogenic microorganisms. <sup>20</sup> A consequence of our finding is that recombinant IFN $\gamma$  treatment may be considered for patients with HCL suffering from serious infection, with facultative intracellular microorganisms.

# ACKNOWLEDGEMENTS

M.G.N. was supported by a Vidi grant of the Netherlands Organisation for Scientific Research.

# REFERENCES

- Cawley JC, Burns GF and Hayhoe FJG. Hairy cell leukemia. Berlin: Springer-Verlag, 1980.
- Bennett C, Vardiman J and Golomb H. Disseminated atypical mycobacterial infection in patients with hairy cell leukemia. Am J Med 1986;80:891-6.
- Van der Meer JWM. Defects in host defense mechanisms. In: Rubin RH, Young LS, eds. Clinical approach to infection in the compromised host. New York: Plenum, 1994:33-66.

# Netherlands The Journal of Medicine

- Kluin-Nelemans JC, Kester MG, Oving I, Cluitmans FH, Willemze R, Falkenburg JH. Abnormally activated T lymphocytes in the spleen of patients with hairy-cell leukemia. Leukemia 1994;8:2095-101.
- Kluin-Nelemans HC, Kester MG, van de Corput L, et al. Correction of abnormal T-cell receptor repertoire during interferon-alpha therapy in patients with hairy cell leukemia. Blood 1998;91:4224-31.
- 6. Van de Corput L, Falkenburg JH, Kluin-Nelemans JC. T-cell dysfunction in hairy cell leukemia: an updated review. Leuk Lymphoma 1998;30:31-9
- Van de Corput L, Falkenburg JH, Kester MG, Willemze R, Kluin-Nelemans JC. Impaired expression of CD28 on T cells in hairy cell leukemia. Clin Immunol 1999;93:256-62.
- Ottenhof TH, Kumararatne D, Casanova JL. Novel human immunodeficiencies reveal the essential role of type-I cytokines in immunity to intracellular bacteria. Immunol Today 1998;19:491-4.
- Endres S, Ghorbani R, Lonnemann G, van der Meer JWM, Dinarello CA. Measurement of immunoreactive interleukin-1 beta from human mononuclear cells: optimization of recovery, intrasubject consistency, and comparison with interleukin-1 alpha and tumor necrosis factor. Clin Immunol Immunopathol 1988;49:424-38.
- Foa R, Massaia M, Cardona S, et al. Production of tumor necrosis factor-alpha by B-cell chronic lymphocytic leukemia cells: a possible regulatory role of TNF in the progression of the disease. Blood 1990;76:393-400.
- Eigler A, Waller-Fontaine K, Moeller J, Hartmann G, Hacker UT, Endres S.
   The hairy cell leukemia cell line Eskol spontaneously synthesizes tumor necrosis factor-alpha and nitric oxide. Leuk Res 1998;22:501-7.
- De Jong R, Altare F, Haagen IA, et al. Severe mycobacterial and Salmonella infections in interleukin-12 receptor-deficient patients. Science 1998;280:1435-8.

- 13. Altare F, Durandy A, Lammas D, et al. Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency. Science 1998;280:1432-5.
- 14. Orlikowsky T, Wang ZQ, Dudhane A, Horowitz H, Conti B, Hoffmann M. The cell surface marker phenotype of macrophages from HIV-1-infected subjects reflects an IL-10-Enriched and IFN-gamma-deprived donor environment. J Interferon Cytokine Res 1996;16:957-62.
- Netea MG, Brouwer AE, Hoogendoorn EH, et al. Two patients with cryptococcal meningitis and idiopathic CD4 lymphopenia: defective cytokine production and reversal by recombinant interferon- gamma therapy. Clin Infect Dis 2004;39:e83-7.
- Paganelli R, Scala E, Capobianchi MR, et al. Selective deficiency of interferon-gamma production in the hyper-IgE syndrome. Relationship to in vitro IgE synthesis. Clin Exp Immunol 1991;84:28-33.
- Netea MG, Kullberg BJ, van der Meer JW. Severely impaired IL-12/IL-18/ IFNgamma axis in patients with hyper IgE syndrome. Eur J Clin Invest 2005;35:718-21
- Grimbacher B, Holland SM, Gallin JI, et al. Hyper-IgE syndrome with recurrent infections - an autosomal dominant multisystem disorder. N Engl J Med 1999;340:692-702.
- Van der Graaf CAA, Netea MG, Drenth JPH, te Morsche RH, van der Meer JWM, Kullberg BJ. Candida-specific interferon-gamma deficiency and Toll-like receptor polymorphisms in patients with chronic mucocutaneous candidiasis. Neth J Med 2003;61:365-9.
- 20. Netea MG, Radstake T, Joosten LA, van der Meer JWM, Kullberg BJ. Salmonella septicemia in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: association with decreased interferon-gamma production and Toll-like receptor 4 expression. Arthritis Rheum 2003;48:1853-7.